The Antigen Presenting Capabilities of Group 3 Innate Lymphoid Cells: Insights Into Immunogenic or Tolerogenic Outcomes for T Cells
European Journal of Immunology · 2025
DOI: 10.1002/eji.70103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Alessia Calabrò und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Pathology "G. Barresi", Laboratory of Immunology and Biotherapy, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Immunity, Innate, Antigen Presentation, Immune Tolerance, CD4-Positive T-Lymphocytes. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union, Italian Ministry of Health, Italian Association for Cancer Research.
Abstract (Originalsprache)
Group 3 innate lymphoid cells (ILC3s) are tissue‐resident lymphocytes distributed across both lymphoid and non‐lymphoid tissues, capable of mounting rapid immune responses. They are defined by expression of the transcription factor RORγt and comprise distinct subsets, including lymphoid tissue inducer‐like cells expressing major histocompatibility complex class II (MHCII). These MHCII⁺ ILC3s can directly present antigens to CD4⁺ T cells, a function regulated by the transcriptional activator CIITA through a pathway similar to thymic epithelial cells. ILC3s contribute to immune homeostasis by limiting effector T cell responses and promoting regulatory T cell differentiation. However, under the influence of distinct cytokine milieus, such as IL‐1β and IFN‐γ, ILC3s undergo a maturation process, upregulating costimulatory molecules and enhancing their antigen‐presenting capacity to activate CD4⁺ T cells. This dual functionality is highly plastic and influenced by tissue‐specific environmental cues, enabling ILC3s to adapt their immunoregulatory roles according to local context. Overall, ILC3s now emerge as critical modulators of T cell activities, balancing tolerance and activation, with significant implications for host defense, autoimmunity, inflammation, and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Pathology "G. Barresi", Laboratory of Immunology and Biotherapy, University of Messina, Messina, Italy.
- Department of Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Experimental Pathology and Immunology-IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
ORCID-Profile: Guido Ferlazzo
Förderung
- European Union
- Italian Ministry of Health
- Italian Association for Cancer Research
- Supporting Researcher Exchange to Promote International Joint Research in Nagoya City University
- European Commission
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Calabrò, A., Yamazaki, S., Ferlazzo, G., & Campana, S. (2025). The Antigen Presenting Capabilities of Group 3 Innate Lymphoid Cells: Insights Into Immunogenic or Tolerogenic Outcomes for T Cells. European Journal of Immunology. https://doi.org/10.1002/eji.70103
Vancouver
Calabrò A, Yamazaki S, Ferlazzo G, Campana S. The Antigen Presenting Capabilities of Group 3 Innate Lymphoid Cells: Insights Into Immunogenic or Tolerogenic Outcomes for T Cells. European Journal of Immunology. 2025. doi:10.1002/eji.70103
BibTeX
@article{Calabr2025,
author = {Calabrò, Alessia and Yamazaki, Sayuri and Ferlazzo, Guido and Campana, Stefania},
title = {The Antigen Presenting Capabilities of Group 3 Innate Lymphoid Cells: Insights Into Immunogenic or Tolerogenic Outcomes for T Cells},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.70103}
}
EUVIMED